Pericarditis resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 306: Line 306:
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
----
----
'''Order tests to identify specific etiologies'''<br>
'''Order tests to identify the specific etiology'''<br>
----
----
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br>
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br>
Line 360: Line 360:
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
----
----
'''Order tests to identify specific etiologies'''<br>
'''Order tests to identify the specific etiology'''<br>
----
----
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br>
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order specifc tests based on the clinical suspicion]]<br>
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Treat according to the etiology]]
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Treat according to the etiology]]
</div>| I01=<div style="float: left; text-align: left; width: 15em; padding:1em;">'''[[Aspirin]]'''<br>
</div>| I01=<div style="float: left; text-align: left; width: 15em; padding:1em;">'''Intitate [[aspirin]] therapy'''<br>
----
----
[[aspirin|High-dose aspirin]]: <br>
'''[[aspirin|High-dose aspirin]]''' <br>
:❑ Orally 800 mg QID or TDS x 7-10 days <BR>
:❑ Orally 800 mg QID or TDS x 7-10 days <BR>
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br>
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br>
Line 373: Line 373:
:❑ [[Omeprazole]] (20 mg/day)  <br>
:❑ [[Omeprazole]] (20 mg/day)  <br>
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]]  <br>
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]]  <br>
'''[[Steroids]]'''<br>
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
----
----
'''[[Steroids]]'''<br>
'''Life style modification'''<br>
----
----
Avoid steroids to treat an initial episode of pericarditis <br>
In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br>
</div>| I04=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''NSAID's'''<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings<br>
</div>| I04=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Initiate medical therapy'''<br>
----
----
'''NSAID's'''<br>
❑ [[Ibuprofen]]: <br>
❑ [[Ibuprofen]]: <br>
:❑ Preferred<br>
:❑ Preferred<br>
Line 391: Line 396:
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR>
:❑ [[Misoprostol]] (600 to 800 mg/day)<BR>
:❑ [[Omeprazole]] (20 mg/day)  <br>
:❑ [[Omeprazole]] (20 mg/day)  <br>
----
 
 
'''[[Colchicine]]'''<br>
'''[[Colchicine]]'''<br>
----
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>
❑ Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>
❑ Can be used alone<BR>
❑ Can be used alone<BR>
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
'''[[Steroids]]'''<br>
❑ Avoid steroids to treat an initial episode of pericarditis  <br>
----
----
'''[[Steroids]]'''<br>
'''Life style modification'''<br>
----
----
Avoid steroids to treat an initial episode of pericarditis <br>
In case of [[pericarditis]], avoid sternous physical activity until symptom resolution<br>
❑ In case of [[myopericarditis]], avoid competitive sports for six months and until normalization of lab findings<br>
</div>}}
</div>}}
{{familytree  | | | | | | | | | | | | |`|-|v|-|'| | | }}
{{familytree  | | | | | | | | | | | | |`|-|v|-|'| | | }}
Line 416: Line 426:
❑ Indication that the underlying cause may not be viral or idiopathic in nature.  <br>
❑ Indication that the underlying cause may not be viral or idiopathic in nature.  <br>
❑ Inpatient therapy <BR>
❑ Inpatient therapy <BR>
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order sepcific tests to identify etiologies and treat accordingly]] <br>
❑ [[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order sepcific tests to identify the etiology and treat accordingly]] <br>
  </div>}}
  </div>}}
{{familytree  | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree  | | | | | | | | | | | | | | | | | | | | | |}}
Line 422: Line 432:


===Treatment of Recurrent Pericarditis===
===Treatment of Recurrent Pericarditis===
Shown below is an algorithm summarizing the management of recurrent [[pericarditis]] in adults.<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693  }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref>
Shown below is an algorithm summarizing the management of recurrent [[pericarditis]] in adults which encompass the '''incessant type''' (relapses on discontinuation of anti-inflammatory) and the '''intermittent type''' (widely varying symptom free interval without medical therapy).<ref name="pmid15120056">{{cite journal| author=Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al.| title=Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. | journal=Eur Heart J | year= 2004 | volume= 25 | issue= 7 | pages= 587-610 | pmid=15120056 | doi=10.1016/j.ehj.2004.02.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15120056  }} </ref><ref name="pmid23998693">{{cite journal| author=Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B et al.| title=American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. | journal=J Am Soc Echocardiogr | year= 2013 | volume= 26 | issue= 9 | pages= 965-1012.e15 | pmid=23998693 | doi=10.1016/j.echo.2013.06.023 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23998693  }} </ref><ref name="pmid15548780">{{cite journal |author=Lange RA, Hillis LD |title=Clinical practice. Acute pericarditis |journal=[[N. Engl. J. Med.]] |volume=351 |issue=21 |pages=2195–202 |year=2004 |month=November |pmid=15548780 |doi=10.1056/NEJMcp041997 |url=}}</ref>


{{Family tree/start}}
{{Family tree/start}}
{{familytree  | | | | | | | | | | A01 | | | | | | | | | | A01=Recurrent pericarditis}}
{{familytree  | | | | | | | | | | A01 | | | | | | | | | | A01=Recurrent [[pericarditis]]}}
{{familytree  | | | | | | | | |,|-|^|-|.| | | | | | | | |}}
{{familytree  | | | | | | | | | | |!| | | | | | | | | | |}}
{{familytree  | | | | | | | | B01 | | B02 | | | | | | | | B01=<div style="float: left; text-align: left; padding:1em;">'''The intermittent type'''<br>
❑ Symptom free interval without therapy  <br>
❑ Widely varying symptom free interval
</div>| B02=<div style="float: left; text-align: left; padding:1em;">'''The incessant type'''<br>
❑ Always relapses on discontinuation of anti-inflammatory<br>
</div>}}
{{familytree  | | | | | | | | |`|-|v|-|'| | | }}
{{familytree  | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; padding:1em;">'''Characterize the clinical, EKG and imaging findings'''<br>
{{familytree  | | | | | | | | | | C01 | | | | | | | | | | | | | | C01=<div style="float: left; text-align: left; padding:1em;">'''Characterize the clinical, EKG and imaging findings'''<br>
❑ Characteristic [[Pericarditis history and symptoms|acute pericarditis symptoms]]  <br>
❑ Characteristic [[Pericarditis history and symptoms|acute pericarditis symptoms]]  <br>
Line 441: Line 444:
❑ Other clinical suspicion:  <br>  
❑ Other clinical suspicion:  <br>  
:❑ Insufficient dose or/and insufficient treatment duration in an autoimmune pericardial disease
:❑ Insufficient dose or/and insufficient treatment duration in an autoimmune pericardial disease
:❑ Early corticosteroid treatment causing augmented viral DNA/RNA replication </div>}}
:❑ [[Corticosteroid]] treatment during the first episode
:❑ Early [[corticosteroid]] treatment causing augmented viral replication </div>}}
{{familytree  | | | | | | | | | | |!| | | | | | | | | | |}}
{{familytree  | | | | | | | | | | |!| | | | | | | | | | |}}
{{familytree  | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Medications'''<br>
{{familytree  | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Initiate medical therapy'''<br>
❑ [[NSAIDs]] or [[aspirin]] <br>
----
:❑ Same regimen as in acute pericarditis management
'''[[NSAIDs]]'''<br>
❑ [[Colchicine]] <br>
Avoid in [[coronary artery disease]] patients<br>
:❑ Same regimen as in acute pericarditis management
❑ [[Ibuprofen]]: <br>
:❑ Effective in cases where NSAIDs failed to prevent relapses
:❑ Preferred<br>
Exercise restriction <br>
:❑ Orally 300-800 mg TDS or QID x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days <br>
[[Indomethacin]]: <br>
:❑ Orally 50 mg TDS x 1-2 weeks<br>
:❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks<br>
 
 
'''[[Aspirin]]'''<br>
❑ Drug of choice in patients with pre-existing [[coronary heart disease]]<br>
❑ [[aspirin|High-dose aspirin]]: <br>
:❑ Orally 800 mg QID or TDS x 7-10 days <BR>
:❑ Gradual tapering by 800 mg/week for 3 additional weeks <br>
❑ Stop [[anticoagulants]] if patient develops [[pericardial effusion]]  <br>
 
 
'''[[Colchicine]]:'''<br>
❑ Effective in cases where NSAIDs failed to prevent relapses<br>
Combination with [[NSAIDs]] (better response rate)<ref name="pmid24552334">{{cite journal| author=Goldfinger S| title=A randomized trial of colchicine for acute pericarditis. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 8 | pages= 780 | pmid=24552334 | doi=10.1056/NEJMc1315351#SA1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24552334  }} </ref> <br>
❑ Can be used alone<BR>
❑ Orally 0.5 mg BID x 3 months (>70 kg)<BR>
❑ Orally 0.5 mg OD x 3 months (≤70 kg) <BR>
 
 
'''Add gastroprotective agents:'''<br>
❑ [[Misoprostol]] (600 to 800 mg/day)<BR>
❑ [[Omeprazole]] (20 mg/day)  <br>
----
'''Life style modification'''<br>
----
❑ Excercise restriction until symptom resolution<br>
<br>
  </div>}}
  </div>}}
{{familytree  | | | | | | | | | | |!| | | | | | | | | | |}}
{{familytree  | | | | | | | | | | |!| | | | | | | | | | |}}
Line 462: Line 496:
{{familytree  | | | | | | | | F01 | | F02 | | | | | | | | F01=<div style="float: left; text-align: left; padding:1em;">'''Taper [[steroids]]'''<br>
{{familytree  | | | | | | | | F01 | | F02 | | | | | | | | F01=<div style="float: left; text-align: left; padding:1em;">'''Taper [[steroids]]'''<br>
❑ Taper dose over a three-month period  <br>
❑ Taper dose over a three-month period  <br>
:❑ If symptoms recur  
❑ If symptoms recur  
::❑ Start the last dose that suppressed the symptoms
::❑ Start the last dose that suppressed the symptoms
::❑ Maintain the dose for 2-3 weeks and then taper
::❑ Maintain the dose for 2-3 weeks and then taper
:❑ Add [[colchicine]] or [[NSAIDs]] at the end of tapering of steroids
❑ Add [[colchicine]] or [[NSAIDs]] at the end of tapering of steroids
  </div>| F02=<div style="float: left; text-align: left; padding:1em;">
  </div>| F02=<div style="float: left; text-align: left; padding:1em;">
❑ Add [[azathioprine]] (75–100 mg/day) or [[cyclophosphamide]]<br>
❑ Add [[azathioprine]] (75–100 mg/day) or [[cyclophosphamide]]<br>
Line 474: Line 508:
{{familytree  | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Pericardiectomy'''<br>
{{familytree  | | | | | | | | | | D01 | | | | | | | | | | D01=<div style="float: left; text-align: left; padding:1em;">'''Pericardiectomy'''<br>
❑ Maintain the patient on [[steroid]] free regimen for several weeks before the procedure
❑ Maintain the patient on [[steroid]] free regimen for several weeks before the procedure
❑'''[[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Clinical testing for specific etiologies]]'''<br></div>}}
❑'''[[Pericarditis 1 resident survival guide#Management#Etiology Specific Management|Order tests to identify the specific etiology and treat accordingly]]</div>}}
{{familytree  | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree  | | | | | | | | | | | | | | | | | | | | | |}}
{{familytree/end}}
{{familytree/end}}
Line 483: Line 517:
! Clinical subgroups!! Specific investigations!! Treatment
! Clinical subgroups!! Specific investigations!! Treatment
|-
|-
| Viral pericarditis|| ❑ Immunocompromised and HIV infected patients <br> ❑ Diagnostic [[pericardiocentesis]]<br> :❑ Analysis of pericardial fluid (transudate or exudate) <br> :❑ [[PCR]] or in-situ hybridisation || ❑ [[CMV]] pericarditis <br> :Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16.<br>❑ [[Coxsackie B]] pericarditis<br> :Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week<br> ❑ [[Adenovirus]] and [[parvovirus B19]] perimyocarditis <br> :Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours
| Viral pericarditis|| ❑ Perform testing for viral etiologies in immunocompromised and [[HIV]] infected patients <br> ❑ Diagnostic [[pericardiocentesis]]<br>:❑ Analysis of [[pericardial fluid]] (transudate or exudate)<br> :❑ [[PCR]] or in-situ hybridisation
|| ❑ [[CMV]] pericarditis: Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16 <br>❑ [[Coxsackie B]] pericarditis: [[Interferon]] alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week<br> ❑ [[Adenovirus]] and [[parvovirus B19]] perimyocarditis: [[Immunoglobulin]] 10 g IV at day 1 and 3 for 6-8 hours
|-
|-
| Purulent pericarditis|| ❑ Diagnostic [[pericardiocentesis]] in cases of high clinical suspicion <br> :❑ [[Gram stain]], acid fast stain, fungal stain, and cultures of the pericardial fluid <br> :❑ Protein, glucose and cell count <br> ❑ Gram stain, acid fast stain, fungal stain, and cultures of other body fluids ||❑ Therapeutic [[pericardiocentesis]] or [[pericardial window]]<br> ❑ [[Pericardiectomy]] may be used in treatment of recurrent pericardial efussion  and in patients with dense adhesions, loculated and thick purulent effusion<br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antimicrobial therapy]] <br> :❑ Intiate antistaphylococcal antibiotic plus [[aminoglycoside]], followed by tailored antibiotic therapy according to pericardial fluid and blood cultures<br> :❑ Empiric regimen can be started for the following <br> ::❑ [[Immunosuppression]]<br> ::❑ Concurrent infection at another body site<br> ::❑ Presence of intravascular lines or prosthetic devices <br> ::❑ Recent antimicrobial therapy <br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antifungal therapy]]
| Purulent pericarditis|| ❑ Diagnostic [[pericardiocentesis]] in cases of high clinical suspicion <br> :❑ [[Gram stain]], acid fast stain, fungal stain, and cultures of the pericardial fluid <br> :❑ [[Protein]], [[glucose]] and cell count <br> ❑ [[Gram stain]], acid fast stain, fungal stain, and [[cultures]] of other body fluids ||❑ Therapeutic [[pericardiocentesis]] or [[pericardial window]]<br> ❑ [[Pericardiectomy]] may be used in treatment of recurrent [[pericardial efussion]] and in patients with dense adhesions, loculated and thick purulent effusion<br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antimicrobial therapy]] <br> :❑ Intiate antistaphylococcal antibiotic plus [[aminoglycoside]], followed by tailored antibiotic therapy according to pericardial fluid and blood cultures<br> :❑ Empiric regimen can be started for the following <br> ::❑ [[Immunosuppression]]<br> ::❑ Concurrent infection at another body site<br> ::❑ Presence of intravascular lines or prosthetic devices <br> ::❑ Recent antimicrobial therapy <br> ❑ [[Pericarditis treatment#Management of Complicated Pericarditis|Antifungal therapy]]
|-
|-
| [[Tuberculous pericarditis]]|| ❑ Diagnostic [[pericardiocentesis]] in all suspected tuberculous pericarditis patients <br> :❑ [[PCR]] of pericardial fluid<br>:❑ High [[adenosine deaminase]] activity and interferon gamma concentration in [[pericardial effusion]] <br> ❑ Pericardial biopsy (rapid diagnosis) <br> ❑ [[Tuberculin skin test]] (not helpful) <br> ❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Culture of sputum, gastric aspirate, and/or urine <br>❑ Enzyme-linked immunospot (ELISPOT)<br> ❑ Serum titres of antimyolemmal and antimyosin antibodies||❑[[Tuberculous pericarditis medical therapy|Anti-tuberculosis chemotherapy]]<br> :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion<br> ❑ [[Pericardiectomy]] is warranted in the setting of persistent [[constrictive pericarditis]] or when no general improvement after 4-8 weeks following antituberculosis chemotherapy<br> ❑ [[Tuberculous pericarditis medical therapy#Role of Corticosteroids in Tuberculous pericarditis|Prednisone]] can be used.
| [[Tuberculous pericarditis]]|| ❑ Diagnostic [[pericardiocentesis]] in all suspected tuberculous pericarditis patients <br> :❑ [[PCR]] of pericardial fluid<br>:❑ High [[adenosine deaminase]] activity and interferon gamma concentration in [[pericardial effusion]] <br> ❑ Pericardial biopsy (rapid diagnosis) <br> ❑ [[Tuberculin skin test]] (not helpful) <br> ❑ [[CT scan]] and/or [[MRI]] of the chest <br> ❑ Culture of sputum, gastric aspirate, and/or urine <br>❑ Enzyme-linked immunospot (ELISPOT)<br> ❑ Serum titres of antimyolemmal and antimyosin antibodies||❑[[Tuberculous pericarditis medical therapy|Anti-tuberculosis chemotherapy]]<br> :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion<br> ❑ [[Pericardiectomy]] is warranted in the setting of persistent [[constrictive pericarditis]] or when no general improvement after 4-8 weeks following antituberculosis chemotherapy<br> ❑ [[Tuberculous pericarditis medical therapy#Role of Corticosteroids in Tuberculous pericarditis|Prednisone]] can be used.
|-
|-
| Neoplastic pericarditis ||❑ [[CT scan]] and/or [[MRI]] of the chest <br>  ❑ Diagnostic [[pericardiocentesis]] ❑ Cytology and tumour markers <br>  ❑ Pericardial biopsy || ❑ Systemic antineoplastic treatment <br> ❑ Assess the life expectancy of the patients before proceeding with the treatment<br> :❑ Better prognosis patients should be treated more aggressively <br> :❑ Advanced [[malignancy]] should be treated palliatively with [[pericardiocentesis]] <br> :❑ Recurrence of pericardial effusion is prevented using any of the following techniques <br> ::❑ Prolonged pericardiocentesis <br> ::❑ Pericardial sclerosis <br> ::❑ Pericardiotomy <br> ::❑ Intrapericardial chemotherapy
| Neoplastic [[pericarditis]] ||❑ [[CT scan]] and/or [[MRI]] of the chest <br>  ❑ Diagnostic [[pericardiocentesis]] when other tests couldnt identify [[malignancy]]<br>❑ Cytology and tumour markers <br>  ❑ Pericardial biopsy || ❑ Systemic antineoplastic treatment <br> ❑ Assess the life expectancy of the patients before proceeding with the treatment<br> :❑ Better prognosis patients should be treated more aggressively <br> :❑ Advanced [[malignancy]] should be treated palliatively with [[pericardiocentesis]] <br> ❑ Recurrence of pericardial effusion is prevented using any of the following techniques <br> :❑ Prolonged pericardiocentesis <br> :❑ Pericardial sclerosis <br> :❑ Pericardiotomy <br> :❑ Intrapericardial chemotherapy
|-
|-
| Pericarditis in renal failure ||❑ Renal function test <br>  ❑ Diagnostic [[pericardiocentesis]] <br>  ❑ Pericardial biopsy || ❑ Uremic pericarditis <br> :❑ [[Hemodialysis]] or [[peritoneal dialysis]]<br> :❑ [[Heparin]]-free haemodialysis should be used <br> ❑ Dialysis-associated pericarditis <br> :❑ [[Pericardiocentesis]] for large effusion <br> :❑ Pericardiotomy in non resolving effusion<br>
| Pericarditis in [[renal failure]] ||❑ Renal function test <br>  ❑ Diagnostic [[pericardiocentesis]] <br>  ❑ Pericardial biopsy || ❑ Uremic pericarditis <br> :❑ [[Hemodialysis]] or [[peritoneal dialysis]]<br> :❑ [[Heparin]]-free haemodialysis should be used <br> ❑ Dialysis-associated pericarditis <br> :❑ [[Pericardiocentesis]] for large effusion <br> :❑ Pericardiotomy in non resolving effusion<br>
|-
|-
| Pericarditis in systemic autoimmune disease || ❑ Diagnostic [[pericardiocentesis]] <br> :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3<br> :❑ Antisarcolemmal antibodies<br> ❑ Exclusion of viral and bacterial etiologies|| ❑ [[NSAIDs]] or [[aspirin]] or [[colchicine]] <br> ❑ Systemic [[corticosteroid]] can be used <br> :❑ Intrapericardial steroids has less side effects and is highly effective
| Pericarditis in systemic [[autoimmune disease]] || ❑ Diagnostic [[pericardiocentesis]] <br> :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3<br> :❑ Antisarcolemmal antibodies<br> ❑ Exclusion of viral and bacterial etiologies|| ❑ [[NSAIDs]] or [[aspirin]] or [[colchicine]] <br> ❑ Systemic [[corticosteroid]] can be used <br> :❑ Intrapericardial steroids has less side effects and is highly effective
|-
|-
|}
|}


==Do's==
==Do's==
*Always suspect [[acute pericarditis]] based on a history of characteristic pleuritic chest pain and on a [[pericardial friction rub]] finding.  Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly.  
*Always suspect [[acute pericarditis]] based on a history of characteristic pleuritic chest pain and on a [[pericardial friction rub]] finding.  Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained [[cardiomegaly]].  
* Initial efforts should focus upon excluding a significant effusion or tamponade.  Suspect acute [[cardiac tamponade]] in any patient presenting with [[Beck's triad]]: [[hypotension]], [[tachycardia]] and distended neck veins (or elevated [[jugular venous pressure]]).<ref name="Sternbach-">{{Cite journal  | last1 = Sternbach | first1 = G. | last2 = Beck | first2 = C. | title = Claude Beck: cardiac compression triads. | journal = J Emerg Med | volume = 6 | issue = 5 | pages = 417-9 | month =  | year =  | doi =  | PMID = 3066820 }}</ref>  
* Focus on excluding a significant effusion or tamponade.  Suspect acute [[cardiac tamponade]] in any patient presenting with [[Beck's triad]]: [[hypotension]], [[tachycardia]], muffled heart sounds and distended neck veins (or elevated [[jugular venous pressure]]).<ref name="Sternbach-">{{Cite journal  | last1 = Sternbach | first1 = G. | last2 = Beck | first2 = C. | title = Claude Beck: cardiac compression triads. | journal = J Emerg Med | volume = 6 | issue = 5 | pages = 417-9 | month =  | year =  | doi =  | PMID = 3066820 }}</ref>  
* [[NSAIDs]] are the mainstay in the treatment of uncomplicated [[acute pericarditis]] and [[ibuprofen]] is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range.
* [[NSAIDs]] are the mainstay in the treatment of uncomplicated [[acute pericarditis]] and [[ibuprofen]] is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range.
* Systemic [[corticosteroid]] therapy should be restricted to autoimmune or [[uremic pericarditis]] and [[ibuprofen]] or [[colchicine]] should be introduced early during tapering of steroids.
* [[Heparin]] is recommended under strict observation for patients who need anticoagulant therapy.
* [[Heparin]] is recommended under strict observation for patients who need anticoagulant therapy.
* Systemic corticosteroid therapy should be restricted to connective tissue diseases, autoreactive or uremic pericarditis.  Intrapericardial application avoids systemic side effects and is highly effective.  Always suggest the use of moderate initial dosing followed by a slow taper.
* Restrict systemic [[corticosteroid]] therapy to [[connective tissue diseases]], autoreactive or uremic pericarditis.  Intrapericardial application avoids systemic side effects and is highly effective.   
* Use moderate initial dosing of steroids followed by a slow taper.
* Introduce [[ibuprofen]] or [[colchicine]] early during tapering of steroids.
* Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation.  
* Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation.  
* Assess for the presence of [[coagulopathy]] or the intake of [[antithrombotic]] medications before choosing the modality of drainage of the pericardial fluid.
* Assess for the presence of [[coagulopathy]] or the intake of [[antithrombotic]] medications before choosing the modality of drainage of the pericardial fluid.

Revision as of 00:08, 23 March 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]

Pericarditis Resident Survival Guide Microchapters
Overview
Causes
Diagnosis
Treatment
Acute Pericarditis
Recurrent Pericarditis
Etiology Specific
Do's
Don'ts

Overview

Pericarditis refers to the inflammation of the fibroelastic sac surrounding the heart (pericardium), and it can be dry, fibrinous or effusive independently from the etiology. Myopericarditis, or perimyocarditis refers to acute pericarditis cases that also demonstrate myocardial inflammation resulting in global or regional myocardial dysfunction, elevations of troponins, creatine kinase MB, myoglobin and tumour necrosis factor.[1] Depending on the time of presentation and duration, pericarditis is divided into acute (<6 weeks), subacute (6 weeks to 6 months) and chronic (>6 months) forms. Acute pericarditis is more common than chronic pericarditis and always suspect acute pericarditis based on a history of characteristic pleuritic chest pain and on a pericardial friction rub finding. NSAIDs are the mainstay in the treatment of acute pericarditis and ibuprofen is the most preferred drug for its favourable effect on the coronary flow.[2]

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Diagnosis

Shown below is an algorithm summarizing the diagnostic approach to acute pericarditis in adults.[2][5][4]

 
 
 
 
 
 
 
 
 
Characterize the symptoms:

Chest pain:

❑ Sudden onset
❑ Sharp or dull, aching and pressure like
❑ Pleuritic (exacerbated by inspiration and coughing)
❑ Retrosternal
❑ Radiation to neck, arms, trapezius muscle ridges
❑ Affected by position (improved by sitting up and leaning forward)
❑ No pain (uremia and tuberculosis pericarditis develop slowly)

Symptoms associated with pericardial effusion:
❑ Without a hemodynamically significant pericardial effusion

❑ No specific symptoms

❑ With a hemodynamically significant pericardial effusion

Fatigue
Breathlessness
Orthopnea
Dizziness
❑ Hoarsenes (recurrent laryngeal nerve compression)
Hiccups (phrenic nerve compression)
Abdominal pain (mesenteric ischemia)
Nausea (diaphragm irritation)
Loss of consciousness
Cool extremities
Peripheral cyanosis
Peripheral edema

Other etiology associated symptoms:
Fever (suggestive of infectious etiology)
Cough (suggestive of infectious etiology)
Palpitations
Malaise
Joint pains (suggestive of autoimmune etiology)
Odynophagia
Weight loss (suggestive of malignant etiology)


Obtain a detailed history:
❑ Infections:

Pneumonia
Tuberculosis
HIV
❑ Travel history
❑ Travel to Central or South America (Chagas disease)
❑ Travel to Central Asia or South Africa or South America (Tuberculosis)[6]
❑ Travel to North and Central America (Ohio and Mississippi River valleys) (Histoplasmosis)
❑ Travel to North America (Blastomycosis)

Medications

❑ Systemic illness

Collagen vascular disease
Hypothyroidism
Inflammatory bowel disease
Malignancy
Uremia

❑ Others

Cardiac surgery
Radiation exposure
Dressler's syndrome
Postpericardiotomy syndrome
Trauma history
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

Vitals


Pulse
Tachycardia (typical)
Bradycardia (in hypothyroidism and uremia)
Pulsus paradoxus (in cardiac tamponade)
Blood pressure
❑ Normal (typical)
Hypotension (in cardiac tamponade)
Temperature
Fever less than 39°C or 102.2°F
Hypothermic (in elderly and renal failure)
Respiratory rate
Tachypnea (typical)

Cardiovascular examination:


Auscultation

❑ Heart sounds
❑ Normal (typical)
❑ New S3 heart sound
❑ Distant and muffled (in cardiac tamponade)
Murmur (for concomitant heart disease)
Pericardial friction rub
❑ High pitched, scratchy or squeaky sound
❑ Best heard at the left sternal border
❑ Best heard with the diaphragm of the stethoscope
❑ Varies in intensity overtime and needs repeated examinations
{{#ev:youtube|watch?v=EUCp_3_vwtw|300}}

Palpation:

Jugular venous pulse
❑ Elevated (in cardiac tamponade and constrictive pericarditis)
Kussmaul sign (in constrictive pericarditis)

Percussion:

❑ Cardiac dullness beyond the apical point of maximal impulse (in pericardial effusion)

Respiratory examination:


Wheeze or rales
Pleural effusion

Abdominal examination:


❑ Pulsatile hepatomegaly (in constrictive pericarditis)
Ascites
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order laboratory tests (urgent):

CBC (leucocytosis)
ESR (elevated)
C reactive protein (elevated)
Serum cardiac troponin I and T
Creatine kinase (CK-MB)
Serum myoglobin
Serum tumour necrosis factor
Serum urea and creatinine


Order electrocardiogram (urgent):


Typical findings in pericarditis

ST segment elevation in leads I, II, aVL, aVF, and V3-V6
PR segment depression
❑ Low-voltage QRS complexes (in large pericardial effusion and constrictive pericarditis)
ST elevation in leads I, II, V2, V3, V4, V5, and V6 depicting acute pericarditis
ST elevation in leads I, II, V2, V3, V4, V5, and V6 depicting acute pericarditis

Electrical alternans (in cardiac tamponade)


Order imaging (urgent):


Chest X-ray

❑ Clear lung fields (typical)
❑ A flask-shaped, enlarged cardiac silhouette (in pericardial effusion and cardiac tamponade)
❑ Lateral view may reveal
❑ Thickened pericardial line (in pericarditis, pericardial effusion)
❑ Irregular contours of cardiac silhouette (in chronic pericarditis, pericardial fibrosis, post surgery, metastasis)
Pericardial effusion


Echocardiography (diagnostic test of choice)

Typical findings in pericarditis
❑ Presence of moderate and large pericardial effusion
❑ Right atrial collapse
❑ Diastolic collapse of right ventricle and left atrium (specific for cardiac tamponade)
❑ Check for concomitant heart disease or paracardial pathology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis of acute pericarditis

Atleast two of the following criteria:
❑ Characteristic chest pain

❑ Sharp and pleuritic that is improved by sitting up and leaning forward

Pericardial friction rub

❑ High pitched, scratchy sound at the left sternal border best heard with diaphragm of the stethoscope
❑ Heard during atrial systole, ventricular systole and rapid ventricular filling during early diastole

❑ Suggestive EKG changes

❑ Diffuse ST elevation with reciprocal ST depression in leads aVR and V1

❑ Suggestive echocardiography changes

❑ New or worsening pericardial effusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
No or equivocal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elevated cardiac enzymes
or
Global or regional myocardial dysfunction on echo
 
 
 
 
 
Suspicion of diagnosis of acute pericarditis

❑ Ongoing fever
❑ Poor response to treatment
❑ Suspicion of hemodynamic compromise

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
Yes
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider cardiac MRI (CMR))[7]
 
Consider alternative diagnosis and treat accordingly
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute pericarditis
 
Myopericarditis
 
Treat as acute pericarditis or myopericarditis if there is delayed enhancement on CMR
 
 
 
 
 
 
 

Treatment

Treatment of Acute Pericarditis

Shown below is an algorithm summarizing the management of acute pericarditis in adults.[2][5][4]

 
 
 
 
 
 
 
 
Acute pericarditis or myopericarditis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High risk features

Fever >38°C
Leucocytosis
❑ Subacute presentation
Cardiac tamponade
❑ Large pericardial effusion
❑ Elevated troponins (myopericarditis)
❑ Concurrent oral anticoagulation
❑ Lack of response to aspirin or NSAIDs after at least 1 wk of therapy
Immunosuppressed state
❑ Acute trauma
❑ Relapsing pericarditis

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Any one of the above high risk features
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inpatient treatment
 
 
 
 
 
Outpatient treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable
 
 
No pre-existing coronary artery disease
 
Pre-existing coronary artery disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate medical therapy

NSAIDs
❑ Avoid in coronary artery disease patients
Ibuprofen:

❑ Preferred
❑ Orally 300-800 mg TDS or QID x 1-2 weeks
❑ Gradual tapering every 2-3 days

Indomethacin:

❑ Orally 50 mg TDS x 1-2 weeks
❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks


Aspirin
❑ Drug of choice in patients with pre-existing coronary heart disease
High-dose aspirin:

❑ Orally 800 mg QID or TDS x 7-10 days
❑ Gradual tapering by 800 mg/week for 3 additional weeks

❑ Stop anticoagulants if patient develops pericardial effusion


Colchicine:
❑ Combination with NSAIDs (better response rate)[8]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)


Add gastroprotective agents:
Misoprostol (600 to 800 mg/day)
Omeprazole (20 mg/day)


Steroids:
❑ Avoid steroids to treat an initial episode of pericarditis


Order tests to identify the specific etiology


Order specifc tests based on the clinical suspicion
Treat according to the etiology


Order pericardiocentesis:


❑ When there is

❑ High suspicion of purulent or neoplastic pericarditis
❑ Effusions > 20 mm in echocardiography in diastole
❑ Large or symptomatic effusions despite one week of medical therapy
 
Click here for management of cardiac tamponade

❑ Immediately transfer the patient to ICU
❑ Telemetry monitoring and frequent vital checks
❑ Call cardiology team immediately
Pericardiocentesis is a life saving procedure in cardiac tamponade
❑ Make sure that the patient is oxygenating well


Initiate medical therapy


NSAIDs
❑ Avoid in coronary artery disease patients
Ibuprofen:

❑ Preferred
❑ Orally 300-800 mg TDS or QID x 1-2 weeks
❑ Gradual tapering every 2-3 days

Indomethacin:

❑ Orally 50 mg TDS x 1-2 weeks
❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks


Aspirin
❑ Drug of choice in patients with pre-existing coronary heart disease
High-dose aspirin:

❑ Orally 800 mg QID or TDS x 7-10 days
❑ Gradual tapering by 800 mg/week for 3 additional weeks

❑ Stop anticoagulants if patient develops pericardial effusion


Colchicine:
❑ Combination with NSAIDs (better response rate)[8]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)


Add gastroprotective agents:
Misoprostol (600 to 800 mg/day)
Omeprazole (20 mg/day)


Steroids:
❑ Avoid steroids to treat an initial episode of pericarditis


Order tests to identify the specific etiology


Order specifc tests based on the clinical suspicion
Treat according to the etiology

 
Initiate medical therapy

NSAID's
Ibuprofen:

❑ Preferred
❑ Orally 300-800 mg TDS or QID x 1-2 weeks
❑ Gradual tapering every 2-3 days
❑ Avoid in coronary artery disease patients

Indomethacin:

❑ Orally 50 mg TDS x 1-2 weeks
❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks
❑ Avoid in coronary artery disease patients
Or

❑ Add gastroprotective agents

Misoprostol (600 to 800 mg/day)
Omeprazole (20 mg/day)


Colchicine
❑ Combination with NSAIDs (better response rate)[8]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)


Steroids
❑ Avoid steroids to treat an initial episode of pericarditis


Life style modification


❑ In case of pericarditis, avoid sternous physical activity until symptom resolution
❑ In case of myopericarditis, avoid competitive sports for six months and until normalization of lab findings

 
Intitate aspirin therapy

High-dose aspirin

❑ Orally 800 mg QID or TDS x 7-10 days
❑ Gradual tapering by 800 mg/week for 3 additional weeks

❑ Add gastroprotective agents

Misoprostol (600 to 800 mg/day)
Omeprazole (20 mg/day)

❑ Stop anticoagulants if patient develops pericardial effusion

Steroids
❑ Avoid steroids to treat an initial episode of pericarditis


Life style modification


❑ In case of pericarditis, avoid sternous physical activity until symptom resolution
❑ In case of myopericarditis, avoid competitive sports for six months and until normalization of lab findings

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Response to treatment
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Follow up

❑ Observe for recurrences or constriction
❑ Assess again at 7 to 10 days for treatment response
❑ At 1 month check blood tests and CRP
❑ Thereafter assess only if symptoms recur

 
Hospital admission

❑ Indication that the underlying cause may not be viral or idiopathic in nature.
❑ Inpatient therapy
Order sepcific tests to identify the etiology and treat accordingly

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Treatment of Recurrent Pericarditis

Shown below is an algorithm summarizing the management of recurrent pericarditis in adults which encompass the incessant type (relapses on discontinuation of anti-inflammatory) and the intermittent type (widely varying symptom free interval without medical therapy).[2][5][4]

 
 
 
 
 
 
 
 
 
Recurrent pericarditis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterize the clinical, EKG and imaging findings

❑ Characteristic acute pericarditis symptoms
❑ Characteristic acute pericarditis EKG changes
❑ Characteristic acute pericarditis echocardiography changes
❑ Massive pericardial effusion, cardiac tamponade, and pericardial constriction are rare
❑ Other clinical suspicion:

❑ Insufficient dose or/and insufficient treatment duration in an autoimmune pericardial disease
Corticosteroid treatment during the first episode
❑ Early corticosteroid treatment causing augmented viral replication
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiate medical therapy

NSAIDs
❑ Avoid in coronary artery disease patients
Ibuprofen:

❑ Preferred
❑ Orally 300-800 mg TDS or QID x 1-2 weeks
❑ Gradual tapering every 2-3 days

Indomethacin:

❑ Orally 50 mg TDS x 1-2 weeks
❑ Gradual tapering every 2-3 days for Rx period of 3-4 weeks


Aspirin
❑ Drug of choice in patients with pre-existing coronary heart disease
High-dose aspirin:

❑ Orally 800 mg QID or TDS x 7-10 days
❑ Gradual tapering by 800 mg/week for 3 additional weeks

❑ Stop anticoagulants if patient develops pericardial effusion


Colchicine:
❑ Effective in cases where NSAIDs failed to prevent relapses
❑ Combination with NSAIDs (better response rate)[8]
❑ Can be used alone
❑ Orally 0.5 mg BID x 3 months (>70 kg)
❑ Orally 0.5 mg OD x 3 months (≤70 kg)


Add gastroprotective agents:
Misoprostol (600 to 800 mg/day)
Omeprazole (20 mg/day)


Life style modification


❑ Excercise restriction until symptom resolution

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple relapses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Add corticosteroids

Prednisone: 1-1.5 mg/kg x 1 month

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive response
 
No response
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taper steroids

❑ Taper dose over a three-month period
❑ If symptoms recur

❑ Start the last dose that suppressed the symptoms
❑ Maintain the dose for 2-3 weeks and then taper

❑ Add colchicine or NSAIDs at the end of tapering of steroids

 

❑ Add azathioprine (75–100 mg/day) or cyclophosphamide

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment failure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pericardiectomy

❑ Maintain the patient on steroid free regimen for several weeks before the procedure

Order tests to identify the specific etiology and treat accordingly
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Etiology Specific Management

Clinical subgroups Specific investigations Treatment
Viral pericarditis ❑ Perform testing for viral etiologies in immunocompromised and HIV infected patients
❑ Diagnostic pericardiocentesis
:❑ Analysis of pericardial fluid (transudate or exudate)
 :❑ PCR or in-situ hybridisation
CMV pericarditis: Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16
Coxsackie B pericarditis: Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week
Adenovirus and parvovirus B19 perimyocarditis: Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours
Purulent pericarditis ❑ Diagnostic pericardiocentesis in cases of high clinical suspicion
 :❑ Gram stain, acid fast stain, fungal stain, and cultures of the pericardial fluid
 :❑ Protein, glucose and cell count
Gram stain, acid fast stain, fungal stain, and cultures of other body fluids
❑ Therapeutic pericardiocentesis or pericardial window
Pericardiectomy may be used in treatment of recurrent pericardial efussion and in patients with dense adhesions, loculated and thick purulent effusion
Antimicrobial therapy
 :❑ Intiate antistaphylococcal antibiotic plus aminoglycoside, followed by tailored antibiotic therapy according to pericardial fluid and blood cultures
 :❑ Empiric regimen can be started for the following
 ::❑ Immunosuppression
 ::❑ Concurrent infection at another body site
 ::❑ Presence of intravascular lines or prosthetic devices
 ::❑ Recent antimicrobial therapy
Antifungal therapy
Tuberculous pericarditis ❑ Diagnostic pericardiocentesis in all suspected tuberculous pericarditis patients
 :❑ PCR of pericardial fluid
:❑ High adenosine deaminase activity and interferon gamma concentration in pericardial effusion
❑ Pericardial biopsy (rapid diagnosis)
Tuberculin skin test (not helpful)
CT scan and/or MRI of the chest
❑ Culture of sputum, gastric aspirate, and/or urine
❑ Enzyme-linked immunospot (ELISPOT)
❑ Serum titres of antimyolemmal and antimyosin antibodies
Anti-tuberculosis chemotherapy
 :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion
Pericardiectomy is warranted in the setting of persistent constrictive pericarditis or when no general improvement after 4-8 weeks following antituberculosis chemotherapy
Prednisone can be used.
Neoplastic pericarditis CT scan and/or MRI of the chest
❑ Diagnostic pericardiocentesis when other tests couldnt identify malignancy
❑ Cytology and tumour markers
❑ Pericardial biopsy
❑ Systemic antineoplastic treatment
❑ Assess the life expectancy of the patients before proceeding with the treatment
 :❑ Better prognosis patients should be treated more aggressively
 :❑ Advanced malignancy should be treated palliatively with pericardiocentesis
❑ Recurrence of pericardial effusion is prevented using any of the following techniques
 :❑ Prolonged pericardiocentesis
 :❑ Pericardial sclerosis
 :❑ Pericardiotomy
 :❑ Intrapericardial chemotherapy
Pericarditis in renal failure ❑ Renal function test
❑ Diagnostic pericardiocentesis
❑ Pericardial biopsy
❑ Uremic pericarditis
 :❑ Hemodialysis or peritoneal dialysis
 :❑ Heparin-free haemodialysis should be used
❑ Dialysis-associated pericarditis
 :❑ Pericardiocentesis for large effusion
 :❑ Pericardiotomy in non resolving effusion
Pericarditis in systemic autoimmune disease ❑ Diagnostic pericardiocentesis
 :❑ Increased number of lymphocytes and mononuclear cells > 5000/mm 3
 :❑ Antisarcolemmal antibodies
❑ Exclusion of viral and bacterial etiologies
NSAIDs or aspirin or colchicine
❑ Systemic corticosteroid can be used
 :❑ Intrapericardial steroids has less side effects and is highly effective

Do's

  • Always suspect acute pericarditis based on a history of characteristic pleuritic chest pain and on a pericardial friction rub finding. Pericarditis should also be suspected in a patient with persistent fever and pericardial effusion or new unexplained cardiomegaly.
  • Focus on excluding a significant effusion or tamponade. Suspect acute cardiac tamponade in any patient presenting with Beck's triad: hypotension, tachycardia, muffled heart sounds and distended neck veins (or elevated jugular venous pressure).[9]
  • NSAIDs are the mainstay in the treatment of uncomplicated acute pericarditis and ibuprofen is the most preferred for its favourable effect on the coronary flow, fewer side effects, and the large dose range.
  • Heparin is recommended under strict observation for patients who need anticoagulant therapy.
  • Restrict systemic corticosteroid therapy to connective tissue diseases, autoreactive or uremic pericarditis. Intrapericardial application avoids systemic side effects and is highly effective.
  • Use moderate initial dosing of steroids followed by a slow taper.
  • Introduce ibuprofen or colchicine early during tapering of steroids.
  • Analyses of pericardial effusion for different etiologies should be ordered according to the clinical presentation.
  • Assess for the presence of coagulopathy or the intake of antithrombotic medications before choosing the modality of drainage of the pericardial fluid.
  • Choose pericardiocentesis rather than surgical drainage as a therapeutic option unless the patient has an indication for surgical drainage.
  • Consider surgical drainage in aortic dissection and myocardial rupture.[10]
  • When surgical drainage is indicated but the patient has severe hypotension prohibiting the induction of anesthesia, perform pericardiocentesis in the operating room before surgery.[10]
  • Monitor closely patients who underwent pericardiocentesis for postdrainage decompensation.

Dont's

  • Never delay treatment whenever cardiac tamponade is suspected.
  • Avoid pericardiocentesis in cases where the diagnosis can be made based on other systemic features or when the effusions are very small or resolving under antiinflammatory treatment
  • Don't perform pericardiocentesis in aortic dissection and ruptured ventricular aneurysm and avoid in cases of uncorrected coagulopathy, anticoagulant therapy, thrombocytopenia < 50,000/mm 3 , small, posterior, and loculated effusions.

References

  1. Imazio M (2012). "Contemporary management of pericardial diseases". Curr Opin Cardiol. 27 (3): 308–17. doi:10.1097/HCO.0b013e3283524fbe. PMID 22450720.
  2. 2.0 2.1 2.2 2.3 Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y; et al. (2004). "Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology". Eur Heart J. 25 (7): 587–610. doi:10.1016/j.ehj.2004.02.002. PMID 15120056.
  3. 3.0 3.1 Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y (2010). "Controversial issues in the management of pericardial diseases". Circulation. 121 (7): 916–28. doi:10.1161/CIRCULATIONAHA.108.844753. PMID 20177006.
  4. 4.0 4.1 4.2 4.3 Lange RA, Hillis LD (2004). "Clinical practice. Acute pericarditis". N Engl J Med. 351 (21): 2195–202. doi:10.1056/NEJMcp041997. PMID 15548780.
  5. 5.0 5.1 5.2 Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B; et al. (2013). "American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography". J Am Soc Echocardiogr. 26 (9): 965–1012.e15. doi:10.1016/j.echo.2013.06.023. PMID 23998693.
  6. "WHO launches World health report 2013". Euro Surveill. 18 (33): 20559. 2013. PMID 23968879.
  7. Khandaker MH, Espinosa RE, Nishimura RA; et al. (2010). "Pericardial disease: diagnosis and management". Mayo Clinic Proceedings. Mayo Clinic. 85 (6): 572–93. doi:10.4065/mcp.2010.0046. PMC 2878263. PMID 20511488. Unknown parameter |month= ignored (help)
  8. 8.0 8.1 8.2 8.3 Goldfinger S (2014). "A randomized trial of colchicine for acute pericarditis". N Engl J Med. 370 (8): 780. doi:10.1056/NEJMc1315351#SA1. PMID 24552334.
  9. Sternbach, G.; Beck, C. "Claude Beck: cardiac compression triads". J Emerg Med. 6 (5): 417–9. PMID 3066820.
  10. 10.0 10.1 Schiavone WA (2013). "Cardiac tamponade: 12 pearls in diagnosis and management". Cleve Clin J Med. 80 (2): 109–16. doi:10.3949/ccjm.80a.12052. PMID 23376916.


Template:WikiDoc Sources Template:WikiDoc Sources